1 / 18

For the TACT Investigators

Clinical Benefit of EDTA Chelation Therapy in Patients with Diabetes in the Trial to Assess Chelation Therapy (TACT).

mandell
Télécharger la présentation

For the TACT Investigators

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Benefit of EDTA Chelation Therapy in Patients with Diabetes in the Trial to Assess Chelation Therapy (TACT) Esteban Escolar, Gervasio A. Lamas, Daniel Mark, Pamela Ouyang, Allan Magaziner, Robin Boineau, Ralph Miranda, Christine Goertz, Yves Rosenberg, Richard Nahin, Richard Nahas, Eldrin Lewis, Lauren Lindblad, Kerry L Lee For the TACT Investigators No disclosures to report The National Center for Complementary and Alternative Medicine (U01AT001156) and the National Heart, Lung and Blood Institute (U01HL092607) provided sole support for this study.

  2. Background • Disodium ethylene diamine tetra acetic acid (EDTA) binds metal cations and permits renal excretion • Since 1956, EDTA chelation has been used to treat atherosclerotic disease without evidence of benefit. • In 2001, NCCAM and NHLBI released an RFA for a definitive trial of EDTA chelation

  3. Background • TACT showed a statistically significant reduction of a combined cardiovascular endpoint (HR 0.82 [95% CI, 0.69-0.99]; p = 0.035) with an EDTA-based infusion regimen in patients with prior MI • There was an interaction between chelation infusion and self-reported diabetes • The present analyses provide greater detail on the effect of chelation therapy in patients with diabetes Lamas GA, Goertz C, Boineau R , et. al. JAMA. 2013;309(12):1241-1250

  4. Design Overview 40 infusions at least 3 hours each; 30 weekly infusions followed by10 maintenance infusions 2-8 weeks apart. Lamas GA, Goertz C, Boineau R, et. al. Am Heart J. 2012 Jan;163(1):7-12. 

  5. Infusion components Chelation Infusion • disodium EDTA, 3 grams (adjusted by GFR) • ascorbic acid, 7 grams • magnesium chloride, 2 grams • potassium chloride, 2 mEq • sodium bicarbonate, 840 mg • pantothenic acid, thiamine, pyridoxine • procaine, 100 mg • unfractionated heparin, 2500 U • sterile water to 500 mL Placebo Infusion • Normal Saline • 1.2% dextrose, 500 mL Lamas GA, Goertz C, Boineau R, et. al. Am Heart J. 2012 Jan;163(1):7-12. 

  6. Inclusion Criteria • Age 50 or older • MI > 6 months prior • Creatinine < 2.0 mg/dL • No coronary or carotid revascularization within 6 months • No active heart failure or heart failure hospitalization within 6 months • Able to tolerate 500cc infusions weekly • No cigarette smoking within 3 months • Signed informed consent

  7. End points • Primary endpoint: • Time to first occurrence of either • death from any cause, • reinfarction, • stroke, • coronary revascularization, or • hospitalization for angina • Secondary endpoint: • Time to first occurrence of either • cardiovascular death, • reinfarction, or • stroke

  8. DM definition • Self-reported diabetes • Treated for diabetes • Fasting blood glucose ≥126 mg/dLprior to enrollment These criteria expanded the population with diabetes from 538 to 633 patients, or 37% of the study subjects

  9. Statistical Analysis • Log-rank test – Comparisons between arms for clinical events. • Intention to treat analysis • Treatment comparisons: • Cumulative event rates - Kaplan-Meier method • RR expressed as HR with 95% CI (Cox model)and nominal p values are reported • Bonferroniadjusted confidence intervals and p-values, adjusted for 9 different subgroup factors

  10. Baselinecharacteristicsofpatients with or without Diabetes For all continuous variables [median (25th, 75th)].

  11. Baseline characteristics of patients with Diabetes by infusion arm For all continuous variables [median (25th, 75th)]. p >0.05 for all comparisons

  12. Primary Endpoint by infusion arm Diabetes Placebo Infusions EDTA Chelation vs. Placebo HR (95% CI): 0.59 (0.44, 0.79); P = 0.0002 Bonferroni Adjusted: (0.39, 0.88); P = 0.002 EDTA Chelation RR = 41% NNT = 6.5 over 5 years CI (4.4, 12.7) Number at Risk: EDTA Chelation 322 286 262 243 217 198 187 177 157 126 74 Placebo 311 270 235 214 187 168 155 134 116 94 63

  13. Primary Endpoint by infusion arm Diabetes No Diabetes EDTA Chelation vs. Placebo HR (95% CI): 0.59 (0.44, 0.79); P = 0.0002 Adjusted: (0.39, 0.88); P = 0.002 EDTA Chelation vs. Placebo HR (95% CI): 1.02 (0.81, 1.28); P = 0.8768 Placebo Infusions EDTA Chelation Number at Risk: EDTA Chelation 322 286 262 243 217 198 187 177 157 126 74 517 474 441 407 371 339 324 299 270 232 155 Placebo 311 270 235 214 187 168 155 134 116 94 63 558 506 466 424 379 347 320 295 268 228 142

  14. Secondary Endpoint by infusion arm Diabetes EDTA Chelation vs. Placebo HR (95% CI): 0.60 (0.39, 0.91); P = 0.0170 Bonferroni Adjusted: (0.32, 1.09); P = 0.153 Number at Risk: EDTA Chelation 322 293 275 259 236 219 210 201 182 149 90 Placebo 311 276 252 231 206 190 180 161 139 117 79

  15. Death by infusion arm - Diabetes EDTA Chelation vs. Placebo HR (95% CI): 0.57 (0.36, 0.88); P = 0.0111 Bonferroni Adjusted: (0.30, 1.06); P = 0.099 Number at Risk: EDTA Chelation 322 303 283 267 251 230 222 211 193 160 101 Placebo 311 293 275 250 227 205 195 174 151 128 83

  16. Limitations • Although this subgroup analysis was prespecified, subgroup findings, regardless of how robust they appear, must be considered hypothesis-generating • A moderate number of patients withdrew consent, limiting somewhat the events that could be accrued and attributed during follow-up

  17. Conclusions • Post-MI diabetic patients age 50 or older on evidence-based medications demonstrated a marked reduction in cardiovascular events with EDTA-based chelationtherapy • These findings support the initiation of clinical trials in patients with diabetes and vascular disease to replicate these findings, and define the mechanisms of benefit • They do not, as yet, constitute sufficient evidence to indicate routine use of chelation therapy for post-MI diabetic patients

  18. This article is now available online in Circulation: Cardiovascular Quality & Outcomes http://circoutcomes.ahajournals.org/content/early/2013/11/19/CIRCOUTCOMES.113.000663

More Related